BG
ABVX

Bellevue Group’s Abivax ABVX Stock Holding History

Bellevue Group’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$117K Buy
+1,048
New +$124K ﹤0.01% 137

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

Bellevue Group's ABVX Position: Q1 2026 in Review

Bellevue Group opened a new position in Abivax (ABVX) in Q1 2026: 1,048 shares worth $117K. The stake represents ﹤0.01% of the portfolio and ranks #137 among its holdings.

254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • Bellevue Group held 1,048 shares of Abivax worth $117K as of Q1 2026.
  • Abivax was a new Bellevue Group position in Q1 2026.
  • Abivax made up ﹤0.01% of Bellevue Group's portfolio in Q1 2026, its #137 holding.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.